• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

    5.080 -0.280 (-5.22%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 126,277
    Open 5.310
    Bid (Size) 4.700 (100)
    Ask (Size) 5.500 (300)
    Prev. Close 5.360
    Today's Range 4.700 - 5.500
    52wk Range 3.280 - 9.821
    Shares Outstanding 41,957,197
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Verrica Pharmaceuticals Q2 Earnings Call Highlights ↗
    Verrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire

    Performance

    YTD
    -38.8%
    -38.8%
    1 Month
    -16.3%
    -16.3%
    3 Month
    -38.3%
    -38.3%
    6 Month
    -23.1%
    -23.1%
    1 Year
    -17.5%
    -17.5%

    More News

    Read More
    News headline image
    Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum ↗
    Via Chartmill
    Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Reports Q4 Earnings Beat and Accelerating Revenue Growth ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica (VRCA) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
    Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
    What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
    The current price of Verrica Pharmaceuticals Inc. - Common Stock is 5.080
    When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 08/07/26 04:00 PM ET
    What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
    The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 213.14M
    How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
    Verrica Pharmaceuticals Inc. - Common Stock has 213M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.